Table 1.
Patient characteristics
| Variable | Total (n = 89) | Atezolizumab (n = 41) | Chemotherapy (n = 48) | p value |
|---|---|---|---|---|
| Age, yr | 66 (38–82) | 66 (38–82) | 67 (44–79) | 0.296 |
| Age group, yr | 0.150 | |||
| < 65 | 34 (38.0) | 19 (46.0) | 15 (31.0) | |
| 65–74 | 38 (43.0) | 13 (32.0) | 25 (52.0) | |
| ≥ 75 | 17 (19.0) | 9 (22.0) | 8 (17.0) | |
| Sex (male) | 79 (89.0) | 37 (90.0) | 42 (88.0) | 0.748 |
| ECOG PS | 0.411 | |||
| 0 | 22 (25.0) | 13 (32.0) | 9 (19.0) | |
| 1 | 46 (52.0) | 21 (51.0) | 25 (52.0) | |
| ≥ 2 | 21 (23.0) | 7 (17.0) | 14 (29.0) | 0.411 |
| History of tobacco use | 0.590 | |||
| Never | 3 (3.0) | 2 (5.0) | 1 (2.0) | |
| Current | 64 (73.0) | 30 (75.0) | 34 (71.0) | |
| Previous | 21 (24.0) | 8 (20.0) | 13 (27.0) | |
| Primary mass, cm | 0.505 | |||
| < 5.3 | 41 (50.0) | 20 (56.0) | 21 (46.0) | |
| ≥ 5.3 | 41 (50.0) | 16 (44.0) | 25 (54.0) | |
| CEA, ng/mL | 0.079 | |||
| < 3.76 | 32 (51.0) | 13 (39.0) | 19 (63.0) | |
| ≥ 3.76 | 31 (49.0) | 20 (61.0) | 11 (37.0) | |
| Brain metastasis at baseline | 29 (33.0) | 13 (32.0) | 16 (33.0) | 1.000 |
| M stage | 0.276 | |||
| M1a | 14 (16.0) | 5 (12.0) | 9 (19.0) | |
| M1b | 20 (22.0) | 7 (17.0) | 13 (27.0) | |
| M1c | 55 (62.0) | 29 (7.01) | 26 (54.0) | |
| Thoracic radiation | 18 (20.0) | 6 (15.0) | 12 (25.0) | 0.293 |
Values are presented as median (range) or number (%).
p-value obtained from chi-squared and Fisher’s exact tests test.
ECOG PS, Eastern Cooperative Oncology Group Performance status; CEA, carcinoembryonic antigen.